Article citationsMore>>

Crizotinib, A.A.C.R. Yielded a High Objective Response Rate for Adult Patients with ALK-Positive Inflammatory Myofibroblastic Tumor.
https://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=1173#.Wy4cXKdKiUk

has been cited by the following article:

Follow SCIRP
Twitter Facebook Linkedin Weibo
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top